Warren C Rizzo MD (He/him)
Osteoarthritis, Rheumatoid Arthritis & Related, Spondyloarthropathy
Senior Medical Director Clinical Development, Pacira Biosciences
Join to View Full Profile
1261 San Julian Place1261 San Julian PlaceSan Marcos, CA 92078
Phone+1 480-235-5888
Dr. Rizzo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Warren Rizzo is a rheumatologist based in San Marcos, CA, with interest in rheumatoid arthritis, osteoarthritis, and spondyloarthropathy. He completed his residency in internal medicine at Mercy Catholic Medical Center from 1986 to 1989, followed by a fellowship in rheumatology at Temple University Hospital from 1989 to 1991, after graduating from the University of Padova in 1985. Dr. Rizzo is experienced in systemic lupus erythematosus and has contributed significantly to the field through key publications on rheumatoid arthritis, including studies published in the Annals of the Rheumatic Diseases. Additionally, he has been involved in clinical trials related to Raynaud's Phenomenon. He is recognized as a Fellow by the American College of Rheumatology. He currently leads a development program at Pacira Biosciences investigating gene therapy for OA of the knee.
Education & Training
Temple University HospitalFellowship, Rheumatology, 1989 - 1991
Mercy Catholic Medical CenterResidency, Internal Medicine, 1986 - 1989
University of PaduaClass of 1985
Certifications & Licensure
AZ State Medical License 2001 - 2027
IA State Medical License 1999 - 2003
PA State Medical License 1987 - 2002
Awards, Honors, & Recognition
- Fellow (FACR) American College of Rheumatology
Clinical Trials
- Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon Start of enrollment: 2016 Feb 01
Publications & Presentations
PubMed
- 145 citationsEfficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III ...Stanley Cohen, Mark C. Genovese, Ernest Choy, Fernando Perez-Ruiz, Alan Matsumoto
Annals of the Rheumatic Diseases. 2017-10-01 - 76 citationsHumoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA)Clifton O. Bingham, Warren Rizzo, Alan Kivitz, Azra Hassanali, Ruchi Upmanyu
Annals of the Rheumatic Diseases. 2015-05-01
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
